We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

130 hedge funds and large institutions have $743M invested in MoonLake Immunotherapeutics in 2025 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 55 increasing their positions, 23 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

176% more call options, than puts

Call options by funds: $37.5M | Put options by funds: $13.6M

175% more capital invested

Capital invested by funds: $270M → $743M (+$473M)

139% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 23

29.2% more ownership

Funds ownership: 59.27% → 88.47% (+29%)

0% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 47

3% less funds holding

Funds holding: 134 → 130 (-4)

Holders
130
Holders Change
-4
Holders Change %
-2.99%
% of All Funds
1.58%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.04%
New
47
Increased
55
Reduced
23
Closed
47
Calls
$37.5M
Puts
$13.6M
Net Calls
+$23.9M
Net Calls Change
+$5.17M

Top Buyers

1
DTC
Deep Track Capital
Connecticut
+$54.4M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$29.3M
3
CAM
Cormorant Asset Management
Massachusetts
+$27.9M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$24.6M
5
LGM
Logos Global Management
California
+$20.6M

Top Sellers

1
ACA
Avoro Capital Advisors
New York
-$14.3M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$10.8M
3
SSA
Schonfeld Strategic Advisors
New York
-$7.59M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.73M
5
IC
Ikarian Capital
Texas
-$3.12M
Name Holding Trade Value Shares
Change 		Change in
Stake
PNC Financial Services Group
126
PNC Financial Services Group
Pennsylvania
$620 -$142 -12 -20%
WA
127
WPG Advisers
Maryland
$40 – – –
IA
128
IFP Advisors
Florida
$13 -$13K -1,100 -100%
GRP
129
Global Retirement Partners
California
$13 +$12 +1 New
RIL
130
Rothschild Investment LLC
Illinois
$13 +$12 +1 New
ACA
131
Avoro Capital Advisors
New York
– -$14.3M -2,000,000 Closed
Adage Capital Partners
132
Adage Capital Partners
Massachusetts
– -$10.8M -1,500,000 Closed
IC
133
Ikarian Capital
Texas
– -$3.12M -435,839 Closed
Marshall Wace
134
Marshall Wace
United Kingdom
– -$2.3M -321,109 Closed
Verition Fund Management
135
Verition Fund Management
Connecticut
– -$1.96M -272,768 Closed
BFM
136
Boothbay Fund Management
New York
– -$1.86M -258,779 Closed
Schroder Investment Management Group
137
Schroder Investment Management Group
United Kingdom
– -$1.22M -195,490 Closed
DC
138
Decheng Capital
California
– -$1.3M -181,600 Closed
EAM
139
Exome Asset Management
New York
– -$1.28M -178,084 Closed
ACM
140
ADAR1 Capital Management
Texas
– -$1.09M -151,495 Closed
ClearBridge Investments
141
ClearBridge Investments
New York
– -$972K -135,496 Closed
CCM
142
Catalio Capital Management
New York
– -$955K -133,131 Closed
Pictet Asset Management
143
Pictet Asset Management
Switzerland
– -$946K -131,991 Closed
CM
144
Caption Management
Oklahoma
– -$651K -90,800 Closed
SFM
145
Sphera Funds Management
Israel
– -$509K -71,010 Closed
Principal Financial Group
146
Principal Financial Group
Iowa
– -$509K -70,943 Closed
EGM
147
Engineers Gate Manager
New York
– -$422K -58,810 Closed
PCM
148
Prelude Capital Management
New York
– -$321K -44,779 Closed
TC
149
TwinBeech Capital
New York
– -$314K -43,735 Closed
TSS
150
Two Sigma Securities
New York
– -$261K -36,405 Closed
4 5
6
7 8

MLTX Hedge Fund Activity: Q4 2025 in Review

130 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q4 2025, worth a combined $743M — up 175% from $270M a quarter earlier.

Fund positioning in MLTX was balanced in Q4 2025: 47 funds opened new positions, 47 closed out, 55 added to existing stakes and 23 trimmed.

The largest buyer was Deep Track Capital, opening a new position worth an estimated $54.4M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $14.3M sold.

  • 130 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q4 2025, down from 134 in Q3 2025.
  • Funds reported $743M of MoonLake Immunotherapeutics stock for Q4 2025, up 175% quarter-over-quarter.
  • 47 funds opened new MoonLake Immunotherapeutics positions in Q4 2025 and 47 closed out, a net change of 0 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q4 2025 was Deep Track Capital, an estimated $54.4M added.
  • The largest MoonLake Immunotherapeutics seller in Q4 2025 was Avoro Capital Advisors, an estimated $14.3M sold.

Based on aggregated 13F filings for Q4 2025.